Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Bayer HealthCare AG
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Safety and Efficacy of Oral BAY 85-8501 in Patients with inflammation of the tubes in the lungs
To assess the safety and tolerability of 28 day oral administration of BAY 85-8501 versus placebo in subjects with non-CF Bronchiectasis (BE)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Placebo controlled, randomized, double-blind, multi-center, multinational Phase IIb study to investigate the efficacy and tolerability of BAY 58-2667 given intravenously in patients with decompensated chronic congestive heart failure
Primary objective of the study is to investigate the safety and efficacy of a titration phase (8 hours) and a maintenance phase (maximum 40 hours) of intravenous BAY 58-2667 in patients with acute dec...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on sorafenib treatment
The objective of this study is to evaluate efficacy and safety of regorafenib in patients with HCC who have progressed after sorafenib
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Phase IIa Efficacy and Safety Trial of capadenoson in Patients with Chronic Stable Angina
The main objective of this study is to demonstrate that chronic administration of BAY 68-4986 for 28 days at doses of 1 mg, 2 mg and 4 mg, is efficacious in a patient population with chronic stable an...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A randomized, double-blind, placebo-controlled, multi-center, parallel group study to assess the efficacy of vardenafil in the treatment of symtomatic Benign Prostatic Hyperplasia
To assess the efficacy, tolerability and safety of vardenafil (10 mg BID) versus placebo in the two month treatment of men with symptomatic BPH.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once daily for five days
Primary objective of the study is to investigate the effect of capadenoson (BAY 68-4986) 4 mg granulate once daily for 5 days on rate control in patients with atrial fibrillation in comparison to base...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Multi-center, open-label, uncontrolled study to investigate the efficacy and safety of the transdermal contraceptive patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene (material no. 80876395) in a 21-day regimen for 13 cycles in 1650 healthy female subjects
The primary objective of this study is to investigate the contraceptive efficacy of the transdermal contraceptive patch (material no. 80876395).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
BAY94-8862 dose finding trial in subjects with chronic heart failure and mild (Part A) or moderate (Part B) chronic kidney disease
Part A The safety and tolerability of 3 oral doses of BAY 94 8862 given once daily over 4 weeks in a randomized, placebo-controleld, double-blind study in subjects with chronic heart failure (CHF) wit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A study investigating the safety of radium-223 dichloride with abiraterone acetate and prednisone/prednisolone given to patients with castration-resistant prostate cancer that has spread to bone, and who never had chemotherapy before
The primary objective is to compare the clinical benefit of radium-223 dichloride versus placebo in combination with abiraterone and prednisone/prednisolone in asymptomatic or mildly symptomatic chem...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
To determine oral bioavailability of the oral liquid formulation and potential food effects
The primary objective of the study is to determine oral bioavailability of the liquid formulation intended for paediatric use and potential food effects in healthy adults.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant